UBS Group Upgrades Beta Bionics (NASDAQ:BBNX) to “Strong-Buy”

Beta Bionics (NASDAQ:BBNX) was upgraded by equities research analysts at UBS Group to a “strong-buy” rating in a note issued to investors on Monday,Zacks.com reports.

BBNX has been the subject of several other research reports. Lake Street Capital upped their price target on Beta Bionics from $35.00 to $40.00 and gave the stock a “buy” rating in a research note on Friday, January 9th. TD Cowen assumed coverage on shares of Beta Bionics in a research report on Monday, January 26th. They set a “hold” rating and a $17.00 price objective for the company. Robert W. Baird set a $28.00 target price on shares of Beta Bionics in a research note on Tuesday, December 16th. Bank of America cut shares of Beta Bionics from a “buy” rating to a “neutral” rating in a report on Friday, January 9th. Finally, The Goldman Sachs Group restated a “buy” rating and issued a $25.00 price objective on shares of Beta Bionics in a research report on Thursday, January 15th. Two research analysts have rated the stock with a Strong Buy rating, six have assigned a Buy rating, four have given a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and an average price target of $26.42.

Beta Bionics Stock Up 6.6%

BBNX opened at $14.78 on Monday. Beta Bionics has a 52 week low of $8.89 and a 52 week high of $32.71. The business has a 50 day moving average price of $23.65 and a two-hundred day moving average price of $22.66. The company has a market cap of $650.76 million and a PE ratio of -3.38.

Insider Activity

In other Beta Bionics news, insider Mike Mensinger sold 7,800 shares of Beta Bionics stock in a transaction dated Friday, January 2nd. The shares were sold at an average price of $29.61, for a total transaction of $230,958.00. Following the completion of the transaction, the insider owned 82,952 shares in the company, valued at approximately $2,456,208.72. The trade was a 8.59% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, CFO Stephen Feider sold 20,000 shares of the stock in a transaction that occurred on Friday, January 2nd. The shares were sold at an average price of $29.53, for a total transaction of $590,600.00. Following the completion of the sale, the chief financial officer owned 42,614 shares in the company, valued at $1,258,391.42. This represents a 31.94% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold a total of 32,490 shares of company stock valued at $960,835 over the last 90 days.

Hedge Funds Weigh In On Beta Bionics

Several hedge funds have recently bought and sold shares of the stock. Eventide Asset Management LLC lifted its position in shares of Beta Bionics by 0.5% in the third quarter. Eventide Asset Management LLC now owns 4,957,252 shares of the company’s stock valued at $98,500,000 after acquiring an additional 24,901 shares in the last quarter. Farallon Capital Management LLC raised its stake in Beta Bionics by 2.6% in the 3rd quarter. Farallon Capital Management LLC now owns 4,313,920 shares of the company’s stock valued at $85,718,000 after purchasing an additional 110,000 shares during the last quarter. Soleus Capital Management L.P. lifted its holdings in Beta Bionics by 12.5% in the 2nd quarter. Soleus Capital Management L.P. now owns 3,820,158 shares of the company’s stock valued at $55,622,000 after purchasing an additional 424,817 shares in the last quarter. Sands Capital Alternatives LLC lifted its holdings in Beta Bionics by 15.0% in the 2nd quarter. Sands Capital Alternatives LLC now owns 3,570,113 shares of the company’s stock valued at $51,981,000 after purchasing an additional 466,331 shares in the last quarter. Finally, Vanguard Group Inc. boosted its stake in shares of Beta Bionics by 213.5% during the 3rd quarter. Vanguard Group Inc. now owns 2,216,185 shares of the company’s stock worth $44,036,000 after purchasing an additional 1,509,217 shares during the last quarter.

About Beta Bionics

Beta Bionics, a clinical-stage medical device company headquartered in Boston, Massachusetts, is focused on revolutionizing the management of type 1 diabetes through automated insulin delivery solutions. The company’s flagship product, the iLet Bionic Pancreas system, is designed to simplify glycemic control by automatically adjusting insulin dosing in response to continuous glucose monitoring data. By integrating advanced algorithmic control with wearable infusion pumps, the iLet aims to reduce the daily burden of diabetes management and improve clinical outcomes for patients.

At the core of Beta Bionics’ offering is its proprietary bionic pancreas software, which can operate in both insulin-only and dual‐hormone modes.